- Home
- BMRC vs EDIT Comparison
BMRC vs EDIT Comparison
Compare BMRC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMRC | EDIT |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.7M | 368.6M |
| IPO Year | 2007 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BMRC | EDIT |
|---|---|---|
| Price | $28.87 | $2.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $31.20 | $6.10 |
| AVG Volume (30 Days) | 103.3K | ★ 2.0M |
| Earning Date | 10-26-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.60% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 1.11 | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $5.16 | N/A |
| P/E Ratio | $24.96 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $23.35 | $1.66 |
| 52 Week High | $30.92 | $3.94 |
Technical Indicators
Market Signals| Indicator | BMRC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 63.21 | 48.97 |
| Support Level | $27.89 | $2.31 |
| Resistance Level | $28.43 | $3.13 |
| Average True Range (ATR) | 0.67 | 0.20 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 99.33 | 44.14 |
Price Performance
Historical ComparisonAbout BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.